

#### Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide Synthetic peptide Catalog # BP6279a

# Specification

# Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide - Product Information

Primary Accession

# <u>095994</u>

# Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide - Additional Information

Gene ID 10551

**Other Names** 

Anterior gradient protein 2 homolog, AG-2, hAG-2, HPC8, Secreted cement gland protein XAG-2 homolog, AGR2, AG2

Target/Specificity

The synthetic peptide sequence used to generate the antibody <a

href=/product/products/AP6279a>AP6279a</a> was selected from the N-term region of human AGR2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide - Protein Information

Name AGR2

Synonyms AG2

Function

Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells (By similarity). Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth. Promotes cell adhesion (PubMed:<a href="http://www.uniprot.org/citations/23274113" target="\_blank">23274113</a>).

**Cellular Location** Secreted. Endoplasmic reticulum {ECO:0000250|UniProtKB:088312}

**Tissue Location** 



Expressed strongly in trachea, lung, stomach, colon, prostate and small intestine. Expressed weakly in pituitary gland, salivary gland, mammary gland, bladder, appendix, ovary, fetal lung, uterus, pancreas, kidney, fetal kidney, testis, placenta, thyroid gland and in estrogen receptor (ER)-positive breast cancer cell lines

# Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### <u>Blocking Peptides</u>

### Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide - Images

# Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide - Background

Anterior gradient 2 (AGR2) is known as a cancer cell marker specifically up-regulated in response to depletion of serum and oxygen. AGR2 has been identified as a tumor marker in primary and secondary cancer lesions, and as a marker for detection of circulating tumor cells (CTCs). Elevated levels of AGR2 are known to increase the metastatic potential of cancer cells, but conditions leading to increased expression of AGR2 are not well understood.

### Anterior Gradient 2 (AGR2) Antibody (N-term) Blocking peptide - References

Zweitzig, D.R., Mol. Cell. Biochem. 306 (1-2), 255-260 (2007)Zhang, Y., Prostate Cancer Prostatic Dis. 10 (3), 293-300 (2007)Fletcher, G.C., Br. J. Cancer 88 (4), 579-585 (2003)